Optimized fosfomycin regimens for treating carbapenem‐resistant Acinetobacter baumannii in critically ill patients with varying degrees of renal function
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Nattapong Tidwong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Fosfomycin, Critical Illness, Microbial Sensitivity Tests. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Fosfomycin has been used to treat carbapenem‐resistant Acinetobacter baumannii (CRAB) infections. However, there is insufficient information on dosage adjustment among critically ill patients with renal impairment. This study aims to evaluate the attainment of PK/PD targets for different dosage regimens of CRAB treatment in critically ill patients based on their renal function. Monte Carlo simulations were conducted to assess the probability of achieving time above the minimum inhibitory concentration (T > MIC) of 80% and 100% and to determine the cumulative fraction response (CFR) against institutional MICs. Our results demonstrated that administering fosfomycin 20–24 g/day to individuals with normal renal function (CrCl ≥60 mL/min) achieved the target at a MIC of ≤64 and ≤32 μg/mL during the first 24 h of treatment and at steady state, respectively. Notably, those with renal impairment achieved higher MIC values at a steady state despite dosage reduction. None of the regimens reached the target CFR. Our study suggested that administering fosfomycin at least 20 g/day to those with normal renal function provides sufficient exposure throughout the treatment course when the MIC value is ≤32 μg/mL. Less aggressive dosing regimens are advisable for patients with renal impairment. Additional clinical studies are necessary to verify our suggestions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
- Department of Pharmaceutical Care, Pharmaceutical Care Training Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
- The University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
- Department of Pharmacy, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
- Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Nattapong Tidwong, Suthanya Chupradit, Suzanne L Parker, Pannee Leelawattanachai, Poramed Winichakoon, Baralee Punyawudho
Zitieren
APA
Tidwong, N., Chanruang, A., Chupradit, S., Parker, S. L., Leelawattanachai, P., Winichakoon, P., & Punyawudho, B. (2024). Optimized fosfomycin regimens for treating carbapenem‐resistant Acinetobacter baumannii in critically ill patients with varying degrees of renal function. Clinical and Translational Science. https://doi.org/10.1111/cts.70038
Vancouver
Tidwong N, Chanruang A, Chupradit S, Parker SL, Leelawattanachai P, Winichakoon P, et al. Optimized fosfomycin regimens for treating carbapenem‐resistant Acinetobacter baumannii in critically ill patients with varying degrees of renal function. Clinical and Translational Science. 2024. doi:10.1111/cts.70038
BibTeX
@article{Tidwong2024,
author = {Tidwong, Nattapong and Chanruang, Anan and Chupradit, Suthanya and Parker, Suzanne L and Leelawattanachai, Pannee and Winichakoon, Poramed and Punyawudho, Baralee},
title = {Optimized fosfomycin regimens for treating carbapenem‐resistant Acinetobacter baumannii in critically ill patients with varying degrees of renal function},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70038}
}
EUVIMED